BioCentury | Aug 13, 2015
Emerging Company Profile

Effective pinchpoint

...eIF4E, in Phase I/II trials for prostate cancer and non-small cell lung cancer (NSCLC); and Weifa ASA...
...over the competition: Isis' compound cannot prevent activation of eIF4E that has already been expressed; Weifa's...
...Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. University of California San Francisco , San Francisco, Calif. Weifa ASA (OSE:WEIFA...
BioCentury | Oct 21, 2013
Company News

Aqualis management update

Aqualis ASA (OSE:AQUA), Oslo, Norway Business: Drug delivery, Cancer, Infectious Transitioned: Ole Eriksen to healthcare CBO from COO WIR Staff cancer Infectious...
BioCentury | Sep 16, 2013
Company News

Clavis, Aqualis Offshore deal

...acquire engineering and marine consultancy firm Aqualis in a NOK70 million ($11.5 million) stock deal. Clavis...
...share purchase agreement and shareholder approval at an October meeting. Carnegie A/S is Clavis' advisor. Clavis...
...treat AML (see BioCentury, April 8 & May 20). Clavis Pharma ASA (OSE:CLAVIS), Oslo, Norway Aqualis...
BioCentury | Sep 9, 2013
Financial News

Clavis proposes rights offering of units

...Clavis Pharma ASA (OSE: CLAVIS), Oslo, Norway Business: Drug delivery, Cancer, Infectious Date announced: 9/4/13 Type...
BioCentury | Jul 11, 2013
Distillery Therapeutics

Indication: Cancer

...is in Phase I/II testing to treat non-small cell lung cancer (NSCLC) and prostate cancer. Clavis...
BioCentury | Jul 1, 2013
Finance

2Q Stock Wrap-Up: If it ain't broke

...in Phase II for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) Clavis Pharma ASA (OSE:CLAVIS...
...life-threatening or fatal hypersensitivity reactions. 5/14/13 Clavis Pharma ASA (OSE:CLAVIS) ND $29.0 0.57 3/31/13 $12.8 Clavis...
BioCentury | Jun 10, 2013
Finance

Finding a 4-leaf clover

...II trial in metastatic pancreatic cancer. The program, which Clovis in-licensed from Clavis Pharma ASA (OSE:CLAVIS...
BioCentury | May 27, 2013
Company News

Clavis management update

...Clavis Pharma ASA (OSE:CLAVIS), Oslo, Norway Business: Drug delivery, Cancer, Infectious Transitioned: Gunnar Manum to acting...
BioCentury | May 27, 2013
Finance

Demand disequilibrium

...decline is due to a combination of cost cutting, fundraisings and clinical setbacks. For instance, Clavis...
...LSE:AKT), London, U.K. Bio-Gal Ltd. , Gibraltar, U.K. Diaxonhit (Euronext:ALEHT), Paris, France Clavis Pharma ASA (OSE:CLAVIS...
BioCentury | May 27, 2013
Company News

Clavis board of directors update

...Clavis Pharma ASA (OSE:CLAVIS), Oslo, Norway Business: Drug delivery, Cancer, Infectious Transitioned: Martin Nes, a director...
Items per page:
1 - 10 of 132
BioCentury | Aug 13, 2015
Emerging Company Profile

Effective pinchpoint

...eIF4E, in Phase I/II trials for prostate cancer and non-small cell lung cancer (NSCLC); and Weifa ASA...
...over the competition: Isis' compound cannot prevent activation of eIF4E that has already been expressed; Weifa's...
...Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. University of California San Francisco , San Francisco, Calif. Weifa ASA (OSE:WEIFA...
BioCentury | Oct 21, 2013
Company News

Aqualis management update

Aqualis ASA (OSE:AQUA), Oslo, Norway Business: Drug delivery, Cancer, Infectious Transitioned: Ole Eriksen to healthcare CBO from COO WIR Staff cancer Infectious...
BioCentury | Sep 16, 2013
Company News

Clavis, Aqualis Offshore deal

...acquire engineering and marine consultancy firm Aqualis in a NOK70 million ($11.5 million) stock deal. Clavis...
...share purchase agreement and shareholder approval at an October meeting. Carnegie A/S is Clavis' advisor. Clavis...
...treat AML (see BioCentury, April 8 & May 20). Clavis Pharma ASA (OSE:CLAVIS), Oslo, Norway Aqualis...
BioCentury | Sep 9, 2013
Financial News

Clavis proposes rights offering of units

...Clavis Pharma ASA (OSE: CLAVIS), Oslo, Norway Business: Drug delivery, Cancer, Infectious Date announced: 9/4/13 Type...
BioCentury | Jul 11, 2013
Distillery Therapeutics

Indication: Cancer

...is in Phase I/II testing to treat non-small cell lung cancer (NSCLC) and prostate cancer. Clavis...
BioCentury | Jul 1, 2013
Finance

2Q Stock Wrap-Up: If it ain't broke

...in Phase II for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) Clavis Pharma ASA (OSE:CLAVIS...
...life-threatening or fatal hypersensitivity reactions. 5/14/13 Clavis Pharma ASA (OSE:CLAVIS) ND $29.0 0.57 3/31/13 $12.8 Clavis...
BioCentury | Jun 10, 2013
Finance

Finding a 4-leaf clover

...II trial in metastatic pancreatic cancer. The program, which Clovis in-licensed from Clavis Pharma ASA (OSE:CLAVIS...
BioCentury | May 27, 2013
Company News

Clavis management update

...Clavis Pharma ASA (OSE:CLAVIS), Oslo, Norway Business: Drug delivery, Cancer, Infectious Transitioned: Gunnar Manum to acting...
BioCentury | May 27, 2013
Finance

Demand disequilibrium

...decline is due to a combination of cost cutting, fundraisings and clinical setbacks. For instance, Clavis...
...LSE:AKT), London, U.K. Bio-Gal Ltd. , Gibraltar, U.K. Diaxonhit (Euronext:ALEHT), Paris, France Clavis Pharma ASA (OSE:CLAVIS...
BioCentury | May 27, 2013
Company News

Clavis board of directors update

...Clavis Pharma ASA (OSE:CLAVIS), Oslo, Norway Business: Drug delivery, Cancer, Infectious Transitioned: Martin Nes, a director...
Items per page:
1 - 10 of 132